Refinement of the Child Amblyopia Treatment Questionnaire (CAT-QoL) using Rasch analysis

Jill Carlton1

  • 1a School of Health and Related Research, HEDS, ScHARR, University of Sheffield , Sheffield.

Strabismus
|April 24, 2019
PubMed

Insights

The Child Amblyopia Treatment Questionnaire (CAT-QoL) was refined using Rasch analysis, resulting in an 8-item instrument. This validated tool measures the impact of amblyopia treatment on children's quality of life.

Area of Science:

  • Ophthalmology
  • Pediatric Health
  • Psychometrics

Background:

  • Amblyopia, a vision disorder in children, significantly impacts quality of life.
  • Existing generic patient-reported outcome measures may not fully capture the specific effects of amblyopia treatment.
  • A validated, child-specific instrument is needed to assess treatment outcomes.

Purpose of the Study:

  • To refine the Child Amblyopia Treatment Questionnaire (CAT-QoL) using Rasch analysis.
  • To improve the psychometric properties of the CAT-QoL for measuring health-related quality of life in children undergoing amblyopia treatment.
  • To develop a reliable and valid measure for assessing the impact of amblyopia treatment.

Main Methods:

  • A multi-center pilot study involving 342 participants was conducted.
  • Rasch analysis techniques were applied to refine the CAT-QoL, examining response categories, item fit, and dependencies.
  • Items with poor fit or significant dependency were removed, and response scales were collapsed to improve the model.

Main Results:

  • Initial analysis identified disordered response categories and poorly fitting items ('cross', 'happy', 'upset with family').
  • After refinement using Rasch analysis, a validated 8-item CAT-QoL instrument with three-level response scales was developed.
  • No statistically significant differential item functioning (DIF) was found based on age, sex, or general health.

Conclusions:

  • The refined 8-item CAT-QoL is a psychometrically sound instrument for measuring quality of life in children with amblyopia.
  • The CAT-QoL can be Rasch scored, providing a quantitative measure of treatment impact (0-16 scale, higher scores indicate worse quality of life).
  • The CAT-QoL offers a valuable, specific alternative to generic measures for assessing amblyopia treatment outcomes in children.

Related Concept Videos

Pedigree Analysis01:35

Pedigree Analysis

Overview
89.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
850
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
973
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.9K